Fig. 3: CCR2 stabilizes β-catenin expression through the AKT/GSK3β pathway.
From: A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer
a A total of 84 genes are quantified using a human signal transduction PCR array. The color scheme represents gene expression changes on a log2 scale. b Five genes reach the cutoff value (fold change >2 or <0.5) in both two groups of cells. c Silencing of CCR2 reduces TOP/FOP transcription activity in regR cells, while ectopic expression of CCR2 increases TOP/FOP transcription activity of CRC cells. d Expression of cytoplasm and nuclear β-catenin in the indicated cell lines, determined by immunoblot. β-actin is used as the cytoplasm protein marker and Histone H3 is used as the nuclear protein marker. e Immunoblot analysis of p-ATK (Ser473), AKT, p-GSK3β (Ser9), GSK3β, and β-catenin in the indicated cell lines. f Immunoblot analysis of p-ATK (Ser473), AKT, p-GSK3β (Ser9), GSK3β, and β-catenin in the cells treated with AKT pathway inhibitor (LY294002). Data represent the mean ± SD and are representative of three independent experiments. **P < 0.01, ***P < 0.001
